Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age Phase 1: ≥ 18 years to ≤ 55 years Phase 2: ≥ 18 years to ≤ 65 years~2. Are male or non-pregnant females who agree to contraceptive requirements.~3. Patients with RT-PCR confirmed COVID-19 in ≤ 72 hours prior to randomization \[Ct ≥ 24\].~4. Have SpO2\<94% (range 90-93%) on room air.~5. Have one or more of the following- dyspnea, fever, cough, respiratory rate ≥ 24 per minute and heart rate up to 120 per minute.~6. Patients who agree to participate in the study and follow all study related procedures~Exclusion Criteria:~1. Require mechanical ventilation~2. Have oxygen saturation less than or equal to 89 percent~3. Patients re-infected with SARS-CoV-2~4. Suspected or proven serious active bacterial fungal viral or other infection~5. Patients with positive skin test with IP~6. Patients with known equine allergies or past medical history of serum sickness~7. Patient who are HIV, HCV, HbsAg positive or immunocompromised~8. Patients with significant co-morbidities at screening~9. Moribund state~10. Pregnant or nursing women~11. Participating in other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Equine COVID-19 Antiserum [F(ab')2] (BSVEQAb) Along with Standard of care (Type: EXPERIMENTAL): Dose of BSVEQAb - 5 mg/kg or 10 mg/kg body weight. It is administered as a single dose intravenously after diluting in 100 -150 ml saline. The infusion will be done over 1 to 2 hours.~Standard of care for treatment of COVID-19 positive patients
- Standard of care. (Type: ACTIVE_COMPARATOR): Treatment as per current treatment guidelines and institutional practice for COVID-19 positive patients will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).